OCT: Valuable for detecting macular pathologies in patients with scleritis

News
Article

Researchers indicated OCT can be vital to a timely diagnosis and treatment for scleritic patients.

A person puts glasses on over their red, inflamed eye. Image credit: ©julia_diak – stock.adobe.com

"OCT plays an important role in measuring inflammatory activity," investigators said. Image credit: ©julia_diak – stock.adobe.com

Hungarian investigators reported the beneficial use of optical coherence tomography (OCT) for detecting macular pathologies in patients with scleritis.1Lilla Smeller, MD, Edit Toth-Molnar, MD, and Nicolette Sohar, MD, are from the Department of Ophthalmology, University of Szeged, Szeged, Hungary.

“OCT is a painless method for examining the details of the ocular structures in vivo with high resolution that has revolutionised patient care for following and treating scleritis patients,” the investigators commented.

Twenty-four patients (17 females, 7 males; 27 eyes) with scleritis were included in the study, all of whom had underwent ophthalmologic examination that included measurements of visual acuity and intraocular pressure, slit-lamp and ophthalmoscopic examinations and spectral-domain OCT (Spectralis, Heidelberg Engineering).

The aims of this study were to investigate patients with scleritis using basic ophthalmologic examination methods and OCT both to identify any macular complications and determine whether the macular complications affect the prognosis and treatment and serve as biomarkers since previously, the macula was not examined in patients with scleritis.

OCT results

The OCT images showed epiretinal membranes (ERM) in 3 cases (12%), cystoid macular oedema (CME) in 3 three cases (12%), diffuse macular oedema (DME) in 1 case (4%) and serous retinal detachment (SRD) in 1 case (4%).

In commenting on the image findings, the investigators concluded, “…besides treating scleritis patients, the examination of their macula by OCT is also very important for detecting any macular complications caused by inflammation, since CME is the leading cause of decreased vision. ERMs are also associated with poor vision. Macular pathologies seen on OCT can modify the management of scleritis.”

They continued, “OCT plays an important role in measuring inflammatory activity, determining the severity of inflammation, choosing the best treatment, the response to treatment and avoiding legal blindness. Biomarkers on OCT in scleritic patients, such as CME, DME, SRD, and ERM, are also very useful in order to find the right diagnosis and treatment in time.”

Reference

1. Smeller L, Toth-Molnar E, Sohar N. Optical coherence tomography: focus on the pathology of macula in scleritis patients. J Clin Med. 2023;12:4825; https://doi.org/10.3390/jcm12144825
Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.